Studies on oral anti-hyperglycemic drugs have been shown in some studies to help and
treat type 2 diabetic patients. The present study was designed to evaluate and compare the
effect of different doses of metformin tablets on metabolic syndrome components in type 2
diabetic women in Gorgan, South East of Caspian Sea.Forty type 2 diabetic patients received
500 mg/day and 1000 mg/day metformin tablets for 12 months and forty healthy women were
included in this study. The ATP III criteria were used to determine metabolic syndrome
components, and lipid profiles, HbA1c and insulin were measured. Significant differences were
found between blood sugar, triglycerides, high-density lipoprotein (HDL)-cholesterol,
hemoglobin A1c (HbA1c) and insulin of the patients received 500 mg/day and 1000 mg/day
metformin monotherapy. The blood sugar, triglycerides and insulin were significantly lower in
patients received 500 and 1000 mg/day metformin than control groups. In both groups, HDL-
cholesterol was higher than control groups, but HbA1c was significantly higher and lower in
patients received 500 and 1000 mg/day metformin than control groups, respectively. In both
study groups, positive significant correlation was found between blood glucose and HbA1c and,
blood glucose and triglyceride levels. Our study showed the efficacy of the 1000 mg/day
metformin monotherapy on better control of blood sugar, HbA1c, triglyceride and HDL-
cholesterol levels, but Metformin had no effect on waist circumference and blood pressure.
Treatment with this dose of metformin may be more beneficial for type 2 diabetic patients than
those other doses.